---
aliases: [LLY, Lilly]
---
#actor #healthcare #pharma #usa #public #ai

**Eli Lilly** — Top pharma by market cap. GLP-1 leader (Mounjaro, Zepbound). AI drug discovery investments.

---

## Why Eli Lilly matters

| Metric | Value |
|--------|-------|
| Market cap | ~$750B |
| Ticker | LLY (NYSE) |
| Focus | GLP-1, oncology, immunology |
| AI angle | Drug discovery, clinical trials |

---

## AI in drug discovery

| Initiative | Description |
|------------|-------------|
| Isomorphic Labs | DeepMind spinoff partnership |
| In-house ML | Target identification, molecule design |
| Clinical trial AI | Patient selection, site optimization |

**Thesis:** AI accelerates drug development, reduces R&D costs, improves success rates.

---

## GLP-1 dominance

| Drug | Indication | Status |
|------|------------|--------|
| Mounjaro | Diabetes | Blockbuster |
| Zepbound | Obesity | Fastest launch ever |

**GLP-1 market:** $100B+ potential, Lilly and [[Novo Nordisk]] duopoly.

---

## Investment case

**Bull:**
- GLP-1 market expanding (obesity epidemic)
- Pipeline depth (oncology, Alzheimer's)
- AI-powered R&D efficiency
- Pricing power in US

**Bear:**
- Valuation stretched
- GLP-1 competition intensifying
- Medicare negotiation risk
- Manufacturing capacity constraints

---

## Related

- [[Agentic AI]] — drug discovery applications
- [[Novo Nordisk]] — GLP-1 competitor
